507211738 04/01/2022

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7258588

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
PETER RANDS	03/23/2022
ELLEN JAMES	03/22/2022
TIFFANIE BENWAY	03/29/2022
ZELAH JOEL	03/22/2022
MARIE LAYZELL	03/22/2022

RECEIVING PARTY DATA

Name:	SMALL PHARMA LTD.
Street Address:	6-8 BONHILL STREET
City:	LONDON
State/Country:	ENGLAND
Postal Code:	EC2A 4BX

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17680411

CORRESPONDENCE DATA

Fax Number: (518)452-5579

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: jessica.carlson@hrfmlaw.com

Correspondent Name: HESLIN ROTHENBERG FARLEY & MESITI P.C.

Address Line 1: 5 COLUMBIA CIRCLE

Address Line 4: ALBANY, NEW YORK 12203

ATTORNEY DOCKET NUMBER:	6126.001
NAME OF SUBMITTER:	KELLIE S. FREDERICKS
SIGNATURE:	/Kellie S. Fredericks/
DATE SIGNED:	04/01/2022

Total Attachments: 8

source=H2303617#page1.tif source=H2303617#page2.tif

> PATENT REEL: 059471 FRAME: 0690

507211738



PATENT REEL: 059471 FRAME: 0691

ASSIGNMENT

WHEREAS we, **Peter Rands**, of London, United Kingdom, **Ellen James**, of London, United Kingdom, **Tiffanie Benway**, of London, United Kingdom, **Zelah Joel**, of London, United Kingdom, and **Marie Layzell**, of London, United Kingdom, hereinafter referred to as the ASSIGNOR, are joint inventors of certain inventions or improvements for which we have made application for Letters Patent to the United States Patent Office, identified as U.S. Patent Application No. **17/680,411**, entitled DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS and

WHEREAS, **Small Pharma Ltd.**, hereinafter referred to as ASSIGNEE, having its principal place of business at 6-8 Bonhill Street, London, England EC2A 4BX, is desirous of acquiring the entire right, title and interest in and to the said Patent Property in any and all countries;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, and intending to be legally bound hereby, ASSIGNOR has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over to said ASSIGNEE, the entire right, title and interest in and to said Patent Property and any and all continuations, divisions, renewals, revivals and substitutes for said Patent Property and to and under any and all additional Letters Patent which may be granted on or as a result thereof in the United States and any and all other countries, and any reissue or reissues or reexaminations or extension or extensions or SPCs of said Letters Patent, and the full right to sue for and recover damages recoverable for past infringement of the same, and for violations of provisional rights having arisen from any published application(s) for said Patent Property, and the right to claim priority based on said Patent Property. ASSIGNOR further assigns to and authorizes said ASSIGNEE to file corresponding applications for Letters Patent in all countries, to be held and enjoyed by said ASSIGNEE, its successors, assigns, nominees or legal representatives, to the full end of the term or terms for which said Letters Patent respectively may be granted, reissued or extended, as fully and entirely as the same would have been held and enjoyed by ASSIGNORS had this assignment, sale and transfer not been made.

It is hereby covenanted that ASSIGNOR has full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed and will not execute any agreement in conflict herewith, and ASSIGNOR further covenants and agrees that it will each time request is made and without undue delay, execute and deliver all such papers as may be necessary or desirable to perfect the title to said Patent Property in said assignee, its successors, assigns, nominees, or legal representatives, and ASSIGNOR agrees to communicate to said ASSIGNEE or to its nominee all known facts respecting said Patent Property, to testily in any legal proceedings, to sign all lawful papers to execute all disclaimers and divisional, continuing, reissue and foreign

1

applications, to make all rightful oaths, and generally to do everything reasonably possible to aid said ASSIGNEE, its successors, assigns, nominees and legal representatives to obtain and enforce for its or their own benefit proper patent protection for said inventions or improvements in any and all countries all at the expense, however, of said ASSIGNEE, its successors, assigns, nominees or legal representatives.

AND ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any country or countries foreign to the United States whose duty it is to issue patents on applications as aforesaid, to issue to said ASSIGNEE, as assignee of the entire right, title and interest, any and all Letters Patent for said Patent Property, including any and all Letters Patent of the United States which may be issued and granted on or as a result of any applications included in said Patent Property in accordance with the terms of this assignment.

IN WITNESS WHEREOF, the undersigned, being properly authorized to execute this Assignment, hereunto sets their hand and seal.

London		23		March	
Signed at	on t	this	day of _		2022
Signature	BA986435				

	London, UK	22nd	March	
Signed at _	· 	on this	day of	2022
Signature	DocuSigned by:	-		

Signed at _	Blandford Forum, UK	on this	March day of	2022.
Signature	DocuSigned by: 8593800A0AEB42D Fiffanie Benway			

	London	22nd	March	
Signed at		_on this	_ day of	_2022
Signature	DocuSigned by: Etlal Joll Decomposed 4FA8460			

Signed at _	London	on this	day of	2022
	DocuSigned by:			
Signature _	47CDA32C7E2048D	_		
N	Aarie Layzell			

Signed by and on behalf of the ASSIGNEE Small Pharma Ltd.

London		23	March
Signed at	on this	day of	2022.

Signature (Name, Title)

Peter Rands, Chief Executive Officer